Advertisement

Advertisement

Hematology Expert Review

Hematologic Malignancies

Selected Abstracts From the 2016 BMT Tandem Meetings

Syed A. Abutalib, MD  /  May 10, 2016

The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research and the American Society of Blood and Marrow Transplantation. Held recently in Honolulu, Hawaii, this year’s BMT Tandem Meetings drew 3,000 attendees from 35 countries, w...

Lymphoma
Leukemia
Immunotherapy

Update on FDA-Approved CAR T-Cell Products

Syed Ali Abutalib, MD, and Bruce L. Levine, PhD  /  February 25, 2019

TISAGENLECLEUCEL IS an anti-CD19 chimeric antigen receptor (CAR) T-cell product approved by U.S. Food and Drug Administration to treat selected hematologic malignancies.1,2 To appreciate the clinical trial findings summarized here, from selected abstracts presented at the 2018 American Society of He...

Lymphoma
Immunotherapy

Update on FDA-Approved CAR T-Cell Products

Syed Ali Abutalib, MD, and Bruce L. Levine, PhD  /  February 25, 2019

AXICABTAGENE CILOLEUCEL (also known as CAR19) is an anti-CD19 chimeric antigen receptor (CAR) T-cell product approved by U.S. Food and Drug Administration to treat selected hematologic malignancies.1 To appreciate the clinical trial findings summarized here, from selected abstracts presented at the ...

Lymphoma

Selected Abstracts From the 2016 ASH Annual Meeting

Syed Abutalib, MD  /  May 10, 2017

Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in various types of high-grade, aggressive non-Hodgkin lymphomas (NHLs), including peripheral T-cell lymphomas, central nerv...

Hematologic Malignancies

Autologous and Allogeneic Hematopoietic Cell Transplantation

Syed Abutalib, MD  /  July 10, 2017

HERE ARE SEVERAL ABSTRACTS selected from the proceedings of the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting clinical trials on autologous and allogeneic hematopoietic cell transplantation for various hematologic malignancies. Additional selected abstract...

Multiple Myeloma

Selected Novel Agents in Development for Multiple Myeloma

Syed Abutalib, MD  /  June 10, 2017

Here are several abstracts selected from the proceedings of the 2016 America Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics for the development for patients with relapsed or refractory multiple myeloma. For full details of these study abstracts, visit ...

Leukemia
Immunotherapy

Update on Treatments Under Study for Chronic Lymphocytic Leukemia

Syed Ali Abutalib, MD, and Sonali M. Smith, MD, FASCO  /  September 25, 2019

The ASCO Post has offered comprehensive coverage of the 2019 ASCO Annual Meeting. To complement this news coverage, here are featured clinical trials of several treatments in chronic lymphocytic leukemia (CLL). They focus on the monoclonal antibody obinutuzumab in combination therapy in the CLL14 tr...

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  /  May 10, 2019

GUEST EDITORS Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Professor and...

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed Ali Abutalib, MD, Naveen Pemmaraju, MD, and L. Jeffrey Medeiros, MD  /  August 25, 2020

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Pemmaraju, and Medeiros highlight the clinically aggressive blastic plasmacytoid dendritic cell neoplasm. For each quiz ques...

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  /  November 10, 2018

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignanci...

Hematologic Malignancies

Updates in Hematopoietic Cell Transplantation

Syed Ali Abutalib, MD, and Navneet Majhail, MD, MS  /  February 25, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic and autologous hematopoietic cell transplantation. For full details...

Lymphoma
Immunotherapy

Highlights of Research in Lymphomas Presented During the EHA25 Virtual Congress

Syed Ali Abutalib, MD, and Brad Kahl, MD  /  August 10, 2020

To complement The ASCO Post’s continued coverage of the virtual edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), here are a few abstracts selected from the meeting proceedings focusing on clinical research in Hodgkin and marginal zone lymphomas. Omission of Rad...

Hematologic Malignancies

Gene Therapy: A March Forward!

Syed A. Abutalib, MD, and Uroosa Ibrahim, MD  /  October 10, 2019

GUEST EDITORS Dr. Abutalib is Associate Director, Hematology and Cellular Therapy Program and Director, Clinical Apheresis Program Cancer Treatment at Centers of America, Zion, Illinois; Associate Professor, Rosalind Franklin University of Medicine and Science; and Founder and Co-Editor of Adva...

Myelodysplastic Syndromes

Novel Treatments of Myelodysplastic Syndromes

Syed Ali Abutalib, MD, and Alan F. List, MD  /  February 10, 2019

AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on seven different studies on new therapeutics in myelodysplastic syndromes (MDS). Among the treatments highlighted here are the erythroid maturation agen...

Hematologic Malignancies

Recent Clinical Trials in Hematopoietic Cell Transplantation Setting for Hematologic Malignancies

Syed Abutalib, MD  /  November 10, 2017

Here is a brief look at the study findings and clinical implications of several recent and important clinical trials in neoplastic hematology. Attention is focused on hematopoietic cell transplantation in a variety of hematologic malignancies, with investigations addressing the role of maintenance...

Hematologic Malignancies
Immunotherapy

Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

Syed Ali Abutalib, MD, and Parameswaran Hari, MD  /  April 10, 2020

The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...

Hematologic Malignancies

Updated WHO Classification of Hematologic Malignancies

Syed A. Abutalib, MD  /  June 25, 2016

WHO last updated its classification of tumors of hematopoietic and lymphoid tissues with a fourth edition of its WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, in 2008, as part of a series of WHO Classification of Tumours monographs. This year, with the support of the Intern...

Leukemia
Immunotherapy

Selected ASH Abstracts on Novel Treatments in Acute Lymphoblastic Leukemia

Syed Ali Abutalib, MD, and Daniel J. DeAngelo, MD, PhD  /  March 10, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed and relapsed or refractory acute lymphobla...

Hematologic Malignancies

Study Findings on Novel Agents in Neoplastic Hematology

Syed A. Abutalib, MD  /  February 25, 2018

HERE IS AN UPDATE on four different studies featured at the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition. Topics focus on advanced systemic mastocytosis, diffuse large B-cell lymphoma (DLBCL), amyloidosis, and myeloproliferative neoplasms.  Systemic Mastocytosis  STU...

Hematologic Malignancies

Updated WHO Classification of Hematologic Malignancies

Syed A. Abutalib, MD  /  June 25, 2016

Question 1: Which statement about the classification of tumors of hematopoietic and lymphoid tissues is true? Correct Answer: A. The revised WHO classification defines distant disease entities that can be reliably diagnosed using proposed criteria. Expert Perspective WHO last updated its classifi...

Hematologic Malignancies

Recent Study Findings in CAR T-Cell Therapy for Neoplastic Malignancies

Syed A. Abutalib, MD  /  December 10, 2017

Here is an update on two recent clinical trials focusing on chimeric antigen receptor (CAR) T-cell therapy for neoplastic malignancies. Highlighted are the findings from an early-phase study in refractory aggressive lymphoma and a study in chronic lymphocytic leukemia after failure of ibrutinib (Imb...

Hematologic Malignancies

New WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD and L. Jeffrey Medeiros, MD  /  December 10, 2017

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignancies...

Hematologic Malignancies

Answers to Hematology Expert Review Questions

Syed A. Abutalib, MD and L. Jeffrey Medeiros, MD  /  December 10, 2017

Question 1  Which statement about epidemiology and clinical features of atypical CML is correct? Correct answer: C. Symptoms of atypical CML may be related to anemia and thrombocytopenia. Expert PerspectiveThe exact incidence of atypical CML is unknown, but the median patient age at diagnosis is ...

Multiple Myeloma
Immunotherapy

Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies

Syed Ali Abutalib, MD, and Shaji K. Kumar, MD  /  September 25, 2020

Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen r...

Multiple Myeloma

Smoldering and Relapsed or Refractory Multiple Myeloma

Syed Abutalib, MD  /  May 25, 2017

Here are several abstracts selected from the proceedings of the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in smoldering and relapsed and/or refractory multiple myeloma. For the full details of these study abstracts, visit http://www....

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  /  July 25, 2018

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignan...

Hematologic Malignancies

Update on Neoplastic Hematology: Review of Recent Clinical Trials

Syed A. Abutalib, MD  /  November 25, 2016

Here is a brief look at the study findings and clinical implications of several recent and important clinical trials in neoplastic hematology. Attention is focused on myelodysplastic syndromes, multiple myeloma, and chronic lymphocytic leukemia. Myelodysplastic Syndromes Clinical Trial:  Randomi...

Hematologic Malignancies

Answers to Hematology Expert Review Questions

 /  July 25, 2018

Question 1  Which of the following is one of the four major criteria for the diagnosis of essential thrombocythemia?  Correct Answer: A. Platelet count ≥ 450 × 109/L.  Expert Perspective  The diagnosis of essential thrombocythemia requires that all four major criteria or the first three major cr...

COVID-19

Hypercoagulability in Critically Ill Patients With COVID-19: Where Do We Stand?

Syed Ali Abutalib, MD, and Jean M. Connors, MD  /  May 25, 2020

“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” ―Hippocrates The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Connors consi...

Leukemia
Lymphoma

Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Syed Ali Abutalib, MD, and John M. Pagel, MD, PhD  /  March 25, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed chronic lymphocytic leukemia (CLL) and sma...

Hematologic Malignancies

Microangiopathic Hemolytic Anemia and Thrombocytopenia: Questions

Syed A. Abutalib, MD, and Jean M. Connors, MD  /  August 25, 2015

Hematology Expert Review is an occasional feature that includes a case report followed by questions, answers, and expert commentary. In the July 25 issue of The ASCO Post, part 1 of a case report was published and focused on diagnosis (see summary below). Here, in part 2, the management of this case...

Leukemia
Lymphoma

Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Syed Ali Abutalib, MD, and John M. Pagel, MD, PhD  /  March 25, 2020

ABSTRACT 355: MURANO study: Four-year analysis confirms sustained benefit (compared to bendamustine and rituximab; n = 195) of time-limited venetoclax/rituximab (n = 194) in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; ClinicalTrials.gov NCT02005471)1 Met...

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  /  March 10, 2018

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignancies...

Multiple Myeloma

Updated International Myeloma Working Group Criteria: Diagnostic Challenges

Syed A. Abutalib, MD, and Ola Landgren, MD, PhD  /  April 25, 2018

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Landgren review the underlying data that shaped the updated International Myeloma Working Group (IMWG) diagnostic criteria for multipl...

Hematologic Malignancies

Answers to Hematology Expert Review Questions

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  /  March 10, 2018

GUEST EDITORS: Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Professor and...

Hematologic Malignancies

Complexities in the Diagnosis and Management of Amyloidosis

Syed A. Abutalib, MD, and Anita D’Souza, MD, MS  /  July 10, 2016

Case Study A 70-year-old man is referred to your clinic for a consultation. Recently, a diagnosis of IgG monoclonal gammopathy of undetermined significance (MGUS) was established. Medical history is significant for essential hypertension, type II diabetes mellitus, hyperlipidemia, and atrial fibr...

Hematologic Malignancies

Complexities in the Diagnosis and Management of Amyloidosis

Syed A. Abutalib, MD, and Anita D’Souza, MD, MS  /  July 10, 2016

Question 1: What is the next best step for this patient? Correct Answer: C. Determination of amyloid subtype. Expert Perspective Amyloidosis encompasses a heterogeneous group of diseases bound by the characteristic deposition of amyloid fibrils in soft tissues and bone marrow, and it could be eit...

Lymphoma

Selected ASH Abstracts on Novel Treatments for Non-Hodgkin Lymphomas

Syed Ali Abutalib, MD, AND Sonali M. Smith, MD, FASCO  /  April 25, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for patients with non-Hodgkin lymphomas (NHLs). For full...

Selected ASH Abstracts on Myelodysplastic Syndromes

SYED ALI ABUTALIB, MD, and ALAN F. LIST, MD  /  February 10, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for myelodysplastic syndromes (MDS), including the first...

Hematologic Malignancies

Update on Neoplastic Hematology: Review of Recent Clinical Trials

Syed A. Abutalib, MD  /  October 10, 2016

Here is a brief look at the study findings and clinical implications of several recent clinical trials on newer treatment options in neoplastic hematology. Attention is focused on several types of leukemia, Hodgkin lymphoma, and multiple myeloma. Leukemia Clinical Trial: INO-VATE ALL phase III t...

Hematologic Malignancies
Immunotherapy

Update on Novel Immunotherapies for Plasma Cell Disorders

Syed Ali Abutalib, MD, and Luciano J. Costa, MD, PhD  /  September 10, 2020

In this installment of The ASCO Post’s Hematology Expert Review, we take a closer look at the monoclonal antibody targeting CD38, daratumumab, in the treatment of amyloid light chain (AL) amyloidosis and resistant multiple myeloma as well as the antibody-drug conjugate belantamab mafodotin-blmf, wh...

CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas: Present and Future

SYED ALI ABUTALIB, MD, AND SATTVA S. NEELAPU, MD  /  February 10, 2020

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel immunotherapies for patients with different types of non-Hodgkin lymphom...

Lymphoma

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  /  December 25, 2019

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the updated World Health Organization (WHO) classification of hematopoietic and ly...

Lymphoma

Q: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  /  December 25, 2015

The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear on page 84 with expert commentary. In the November 10 issue of The ASCO Post, part 2 of...

Lymphoma

A: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  /  December 25, 2015

Question 1: Based on the rationale for the current “standard of care” for primary diffuse large B-cell lymphoma of the CNS, what is the optimal induction therapy? Correct Answer: C. A high-dose methotrexate–based regimen. Expert Perspective Untreated primary diffuse large B-cell lymphoma of the C...

Lymphoma

Update on Newer Treatments in Non-Hodgkin Lymphomas

Syed Ali Abutalib, MD, and Matthew Lunning, DO  /  March 10, 2019

AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several different studies on new therapeutics in non-Hodgkin lymphomas (NHLs), including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL)...

Leukemia

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Syed A. Abutalib, MD, and Katharina Fleischhauer, MD  /  October 25, 2016

Case Study A 33-year-old white male is diagnosed with acute myeloid leukemia (AML) with complex cytogenetics. A decision is made in favor of performing allogeneic hematopoietic cell transplantation in first complete remission. The patient has a 35-year-old brother who is healthy and motivated to ...

Leukemia

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Syed A. Abutalib, MD, and Katharina Fleischhauer, MD  /  October 25, 2016

Question 1: Which statement about donor selection for allogeneic hematopoietic cell transplant is correct? Correct Answer: C. If a donor is available, the genotypic identity between the patient and his brother should be established by typing the patient’s parents; if this is not possible, the broth...

Hematologic Malignancies
COVID-19

Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia

Syed Ali Abutalib, MD and Saad Z. Usmani, MD, FACP  /  June 10, 2020

GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-...

Hematologic Malignancies

Study Findings on Myeloproliferative Neoplasms Including Systemic Mastocytosis

Syed Ali Abutalib, MD, and Ruben A. Mesa, MD, FACP  /  December 25, 2018

HERE IS AN UPDATE on six different studies featured at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. Topics focused on novel treatments for myelofibrosis, polycythemia vera and essential thrombocythemia, as well as systemic mastocytosis. Myelofibrosis ABSTRACT...

Advertisement

Advertisement



Advertisement